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INTRODUCTION
Congenital complete atrioventricular block (AVB)without cardiac malformation occurs in 1-15000
to 1-20000 pregnancies1,2. It is a permanent, practical-
ly irreversible and potentially fatal complication3. In
more than 90% of cases results from neonatal lupus ery-
thematosus through transplacental passage of antibo -
dies anti-SSA/Ro and/or anti-SSB/La2.  Maternal
admi nistration of high-dose oral fluorinated steroids
may reverse or inhibit progression of first and second
degree AVB. However, in the presence of a third degree
AVB the therapeutical results have been inconsistent. 
The authors present a case of congenital complete
AVB and a review of the literature.
CASE REPORT
A 34-year-old primiparous woman was referred to our
Maternity at the 24th week of gestation, due to fetal
bradycardia detected on a routine ultrasound performed
two weeks earlier. The previous pregnancy resulted in
a healthy child.
Her medical history was irrelevant. Our initial eva -
luation included a fetal ultrasound and echocardiogram
and maternal autoantibody screening, with emphasis
on testing anti-nuclear antibody (ANA), anti double-
-stranded DNA antibody (anti-dsDNA) and anti-ex-
tractable nuclear antigens (ENA), particularly anti-
-SSA/Ro and anti-SSB/La (Table I). Fetal ultrasound
revealed normal fetal growth (25th percentile) with nor-
mal umbilical and mean cerebral artery doppler scans.
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Fetal echocardiogram showed a sinus bradycardia with
heart rates of 57-60 bpm without associated structural
heart defects, atrioventricular (AV) regurgitation or
pericardial effusions. Maternal anti-SSA/Ro antibo -
dies were detected.
Fetal echocardiogram repeated one week later re-
vealed an alternating second to third degree heart block
with atrial rate of 120 bpm and ventricular rate of 58-
-60 bpm.The mother was started on oral dexametha-
sone (4mg/day) on the 25th week of gestation, which
was discontinued 6 weeks after, since there was no re-
verse in the AV block. Prior to the institution of the
fluorinated steroids, 75g oral glucose tolerance test was
performed within normal range values. 
Regular fetal echocardiograms confirmed complete
AV block without heart failure, pericardial effusions
or atrioventricular impairment. At the 31st week of ges-
tation a fetal brain magnetic resonance imaging
showed normal brain, cerebellum and brain stem mor-
phology, with no signs of intracranial hemorrhage or
encephaloclastic lesions. A mild asymmetry of the la -
teral ventricles was identified.
At the 35th week of gestation there was a slight in-
crease in maternal arterial blood pressure (140/90
mmHg) without proteinuria. Fetal growth fell to 15th
percentile with normal umbilical and mean cerebral
artery doppler scans. There was no fetal hydrops or
signs of heart failure throughout the entire pregnancy.
Due to a fall in atrial and ventricular rates (110 bpm
and <50 bpm, respectively) an elective cesarean section
was performed at 37 weeks of gestation. The newborn
had an Apgar score of 8/8 and weighted 2320g. Heart
rate at birth was above 50 bpm. The newborn was
transferred immediately to our Pediatric Cardiology
Unit. Electrocardiogram confirmed a complete AVB
with a stable heart rate of 40-50 bpm. On the 8th day
of life an epicardical pacemaker was implanted. Post-
natal echocardiogram reaffirmed the absence of struc-
tural heart defects or signs of heart failure. The new-
born was discharged at the 20th day. 
Maternal blood pressure normalized in the postpar-
tum period. 
TABLE I. AUTOANTIBODIES PANEL
Blood Test 25th week 33rd week 3 weeks postpartum
ANA Positive (1/640) Positive (1/640) Positive (1/320)
Anti-dsDNA Negative Negative Negative
Anti-SSA/Ro Positive Positive Positive
Anti-SSB/La Negative Negative Negative
Lupic anticoagulant Negative Negative Negative
Anti-cardiolipin IgG/IgM Negative/Negative Negative/Negative Uncertain/Negative
Anti-β2GP1 IgG/IgM Negative/Negative Negative/Negative Negative/Negative
Reumathoid Factor Positive Negative
Anti-smooth muscle Negative Negative Negative
Anti-RNP Negative Negative Negative
C’3 1.37 (0.90 – 1.80) 1.70 (0.90 – 1.80) 1.17 (0.90 – 1.80)






C-ANCA / P-ANCA Negative/Negative
Anti-TPO 1.0 (<9)
Anti-TG <0.9 (<4)
ANA: anti-nuclear antibody; Anti-dsDNA: anti double-stranded DNA antibody; Anti-β2GP1:  anti beta2 glycoprotein 1 antibody; Anti-RNP:
anti-ribonucleoprotein; Anti-Scl-70: anti topoisomerase I antibody; C-ANCA: Cytoplasmic antineutrophil cytoplasmic antibodies; P-ANCA:
Perinuclear Anti-Neutrophil Cytoplasmic Antibodies; Anti-TPO: Anti-thyroid peroxidase antibody; Anti-TG: Anti-thyroglobulin antibody
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genital AVB or SLE-associated rash, concomitant
treatment with prednisone and gestational age under
12 weeks were required. The authors concluded that
IV-Ig was ineffective in preventing congenital AVB or
reducing maternal antibodies titers8,12. In the same
year, Pisoni published a similar study with 24 pregnant
women whose offspring in prior pregnancies deve -
loped congenital AVB. Gestational age under 12 weeks
and positive anti-SSA/Ro and/or anti-SSB/La were
mandatory criteria for enrollment. Likewise, efficacy
of IV-Ig in preventing congenital AVB was not esta -
blished8,13.
Hydroxychloroquine is the most recent line of in-
vestigation for congenital AVB treatment. In 2010, a
retrospective case-control study involving 50 children
whose mothers had SLE and documented anti-
-SSA/Ro and/or anti-SSB/La antibodies and 151
controls found no significant differences in pregnan-
cy outcomes between the group treated with hydro -
xychloroquine and the control group. Nevertheless, the
authors suggested that hydroxychloroquine may de-
crease the risk of developing neonatal cardiac SLE8,14.
Currently available data does not demonstrate effi-
cacy of any pharmacological treatment in preventing or
avoiding progression of congenital heart block. Two-
-thirds of these children will require a pacemaker with-
in the first year of life and some will develop car-
diomyopathy1,2,9. After an affected pregnancy, the risk
of another fetus with congenital AVB increases at least
10-fold8.
In our case fluorinated corticosteroids were not ef-
fective in preventing progression to third degree AVB.
The lack of prospective and randomized controlled tri-
als that support a beneficial effect of steroids, IV-Ig or
hydroxychloroquine for treatment of complete con-
genital AVB requires a careful risk-benefit analysis be-
fore initiating therapy.
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Virtually all mothers of fetuses with isolated AVB will
have a connective tissue disease - Systemic Lupus Ery-
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